000166717 001__ 166717
000166717 005__ 20240229133528.0
000166717 0247_ $$2doi$$a10.1038/s41408-020-00390-3
000166717 0247_ $$2pmid$$apmid:33414374
000166717 0247_ $$2altmetric$$aaltmetric:97296931
000166717 037__ $$aDKFZ-2021-00064
000166717 041__ $$aeng
000166717 082__ $$a610
000166717 1001_ $$00000-0002-4000-6904$$aBaertsch, Marc-Andrea$$b0
000166717 245__ $$aLenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
000166717 260__ $$aLondon [u.a.]$$bNature Publishing Group$$c2021
000166717 3367_ $$2DRIVER$$aarticle
000166717 3367_ $$2DataCite$$aOutput Types/Journal article
000166717 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1610440870_25477
000166717 3367_ $$2BibTeX$$aARTICLE
000166717 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166717 3367_ $$00$$2EndNote$$aJournal Article
000166717 520__ $$aLenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m2 i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25 mg p.o., days 1-21 of 28 day cycles) followed by 10-15 mg/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91% vs. 33%) due to different tandem ASCT strategies. In the LEN and BTZ cohort, 43% and 46% of patients completed 2 years of MT as intended (p = 0.57). Progression-free survival (PFS; HR = 0.83, p = 0.18) and overall survival (OS; HR = 0.70, p = 0.15) did not differ significantly with LEN vs. BTZ MT. Patients with <nCR after first ASCT were assigned tandem ASCT in both trials. In patients with <nCR and tandem ASCT (LEN: n = 54 vs. BTZ: n = 84), LEN MT significantly improved PFS (HR = 0.61, p = 0.04) but not OS (HR = 0.46, p = 0.09). In conclusion, the significant PFS benefit after eliminating the impact of different tandem ASCT rates supports the current standard of LEN MT after ASCT.
000166717 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000166717 588__ $$aDataset connected to CrossRef, PubMed,
000166717 7001_ $$00000-0002-6226-1252$$aMai, Elias K$$b1
000166717 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b2$$udkfz
000166717 7001_ $$aBertsch, Uta$$b3
000166717 7001_ $$aSalwender, Hans J$$b4
000166717 7001_ $$aMunder, Markus$$b5
000166717 7001_ $$00000-0002-7785-2565$$aFuhrmann, Stephan$$b6
000166717 7001_ $$aDührsen, Ulrich$$b7
000166717 7001_ $$aBrossart, Peter$$b8
000166717 7001_ $$aNeben, Kai$$b9
000166717 7001_ $$aSchlenzka, Jana$$b10
000166717 7001_ $$aKunz, Christina$$b11
000166717 7001_ $$aRaab, Marc S$$b12
000166717 7001_ $$aHillengaß, Jens$$b13
000166717 7001_ $$aJauch, Anna$$b14
000166717 7001_ $$aSeckinger, Anja$$b15
000166717 7001_ $$aHose, Dirk$$b16
000166717 7001_ $$aLuntz, Steffen$$b17
000166717 7001_ $$aSonneveld, Pieter$$b18
000166717 7001_ $$aLokhorst, Henk$$b19
000166717 7001_ $$aMartin, Hans$$b20
000166717 7001_ $$aGoerner, Martin$$b21
000166717 7001_ $$aHoffmann, Martin$$b22
000166717 7001_ $$aLindemann, Hans-Walter$$b23
000166717 7001_ $$aBernhard, Helga$$b24
000166717 7001_ $$aBlau, Igor W$$b25
000166717 7001_ $$aScheid, Christof$$b26
000166717 7001_ $$aBesemer, Britta$$b27
000166717 7001_ $$00000-0001-9422-6614$$aWeisel, Katja C$$b28
000166717 7001_ $$aHänel, Mathias$$b29
000166717 7001_ $$aDürig, Jan$$b30
000166717 7001_ $$aGoldschmidt, Hartmut$$b31
000166717 7001_ $$aGroup, German-Speaking Myeloma Multicenter$$b32$$eCollaboration Author
000166717 773__ $$0PERI:(DE-600)2600560-8$$a10.1038/s41408-020-00390-3$$gVol. 11, no. 1, p. 1$$n1$$p1$$tBlood cancer journal$$v11$$x2044-5385$$y2021
000166717 909CO $$ooai:inrepo02.dkfz.de:166717$$pVDB
000166717 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000166717 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000166717 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000166717 9141_ $$y2021
000166717 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD CANCER J : 2018$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-09-05
000166717 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBLOOD CANCER J : 2018$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-05
000166717 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-05
000166717 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000166717 980__ $$ajournal
000166717 980__ $$aVDB
000166717 980__ $$aI:(DE-He78)C060-20160331
000166717 980__ $$aUNRESTRICTED